MORRISTOWN, New Jersey – January 8, 2016 – Alitair Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on respiratory health, today announced the issuance of U.S. Patent No. 9,211,292, covering its prescription drug overdose reduction technology, ODR™ .
MORRISTOWN, New Jersey – January 21, 2014 – Alitair Pharmaceuticals, Inc., a revenue-stage pharmaceutical company with multiple respiratory product candidates in development, today announced the issuance of U.S. Patent No. 8,617,602 from the United States Patent and Trademark Office (USPTO) for its ion exchange resin drug delivery technology, REA™.
MORRISTOWN, New Jersey – January 7, 2014 – Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development (OOPD) of the Food and Drug Administration (FDA) has granted orphan drug designation for its drug candidate, Erdosteine®, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties.
The Cough Company Is Now Alitair Pharmaceuticals, Inc.